Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Roche Wins FDA Approval For Tecentriq And Lurbinectedin Combination Cutting Risk Of Progression By 46% And Death By 27%

Author: Benzinga Newsdesk | October 03, 2025 02:00am
  • Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1
  • First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help address the high rate of relapse in ES-SCLC2
  • Regimen recommended in National Comprehensive Cancer Network® Guidelines for SCLC*3

Posted In: RHHBF RHHBY RHHVF


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist